Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
shooting games
Popular Articles
Natural Remedies

Nexavar® In Combination With Chemotherapy Shown To Extend Progression-Free Survival In Patients With Advanced Breast Cancer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that their first cooperative group-sponsored randomized Phase II trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar® (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Study findings demonstrated that the median progression-free survival was extended in patients treated with Nexavar and capecitabine compared to patients receiving capecitabine and placebo. These results were statistically significant (p-value = 0.0006). In this trial, the safety and tolerability of the combination was as expected and did not show any new or unexpected toxicities. A complete data analysis from this study is expected to be presented at an upcoming scientific meeting.
generic viagra online
Article In Nature Solves 3 Major Puzzles About The Workings Of A Famous Enzyme Involved In DNA Repair
The "sloppier copier" discovered by USC biologists is also the best sixth man in the DNA repair game, an article in the journal Nature shows.
News of the day
800th Implant Of World's Only Approved Total Artificial Heart Performed By Heart And Diabetes Center NRW
On June 12, the Heart and Diabetes Center NRW in Bad Oeynhausen, Germany, performed the 800th implant of the SynCardia temporary CardioWest™ Total Artificial Heart. The 60-year-old patient, who was suffering from biventricular failure, was listed in stable condition post-implant.
Oncology

Advance In Bowel Cancer Test Research

Australian researchers have developed gene expression biomarkers which can accurately discriminate pre-cancerous and cancerous colorectal growths from non-cancerous controls. Being presented today at the Digestive Disease Week conference in Chicago, the preliminary findings are the result of a collaborative study - involving CSIRO, Flinders University and Australian healthcare company, Clinical Genomics Pty Ltd - designed to develop an improved screening/diagnostic test for detecting bowel cancer and significant pre-cancer lesions. "If we can now show that the levels of these biomarkers in blood or stool also correlate strongly with disease state in a large group of patients with cancer or pre-cancer lesions (ie adenomatous polyps) we may have the basis for a very important new diagnostic weapon in the fight against bowel cancer," says CSIRO"s Preventative Health National Research Flagship Theme Leader in Colorectal Cancer and Gut Health, Dr Trevor Lockett. According to Professor Graeme Young from Flinders University"s Centre for Cancer Prevention and Control, regular screening for bowel cancer in people aged 50 years and over is a powerful tool for reducing the impact of the disease in Australia. "If we can develop a screening test that can point to the presence of clinically important pre-cancerous adenomas which are then removed during follow-up colonoscopy, we will actually be able to prevent the occurrence of bowel cancer in some cases," Professor Young says. The CEO of Clinical Genomics Pty Ltd, Lawrence La Pointe, says if a more robust screening test for bowel cancer and especially pre-cancer lesions emerges, the research team will have achieved a major advance likely to further improve screening outcomes and more precisely identify those people most likely to benefit from colonoscopic investigation. Digestive Diseases Week is the world"s largest gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Clinical Genomics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009